Search research articles
Contact Us
Filters
Showing results (1-10 of 68) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2011
Inclusion of patients with brain metastases in phase I trials: an unmet need
Mrinal M Gounder, David R Spriggs
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology
|
June 29, 2004
Non-kinase second-messenger signaling: new pathways with new promise
Gregory M Springett, Hiroaki Kawasaki, David R Spriggs
Molecular Cancer Therapeutics
|
August 6, 2011
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents
Thapi D Rao, Nestor Rosales, David R Spriggs
Cancer
|
August 24, 2005
Presentation and subsequent publication rates of phase I oncology clinical trials
Luis H Camacho, Jennifer Bacik, Alexander Cheung, et al.
Journal of Translational Medicine
|
April 19, 2015
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru, Roisin O'Cearbhaill, Swati Pendharkar, et al.
Clinical Trials (London, England)
|
October 2, 2008
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
Alexia Iasonos, Andrew S Wilton, Elyn R Riedel, et al.
Gynecologic Oncology
|
February 22, 2002
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
Don S Dizon, Paul J Sabbatini, Carol Aghajanian, et al.
Biophysics Reviews
|
April 12, 2021
Addressing cervical cancer screening disparities through advances in artificial intelligence and nanotechnologies for cellular profiling
Zhenzhong Yang, Jack Francisco, Alexandra S Reese, et al.
Cancers
|
June 4, 2020
Galectins and Ovarian Cancer
Chisa Shimada, Rui Xu, Linah Al-Alem, et al.
Cancers
|
November 2, 2019
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Chiara Bellio, Celeste DiGloria, David R Spriggs, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 68) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2011
Inclusion of patients with brain metastases in phase I trials: an unmet need
Mrinal M Gounder, David R Spriggs
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology
|
June 29, 2004
Non-kinase second-messenger signaling: new pathways with new promise
Gregory M Springett, Hiroaki Kawasaki, David R Spriggs
Molecular Cancer Therapeutics
|
August 6, 2011
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents
Thapi D Rao, Nestor Rosales, David R Spriggs
Cancer
|
August 24, 2005
Presentation and subsequent publication rates of phase I oncology clinical trials
Luis H Camacho, Jennifer Bacik, Alexander Cheung, et al.
Journal of Translational Medicine
|
April 19, 2015
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru, Roisin O'Cearbhaill, Swati Pendharkar, et al.
Clinical Trials (London, England)
|
October 2, 2008
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
Alexia Iasonos, Andrew S Wilton, Elyn R Riedel, et al.
Gynecologic Oncology
|
February 22, 2002
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
Don S Dizon, Paul J Sabbatini, Carol Aghajanian, et al.
Biophysics Reviews
|
April 12, 2021
Addressing cervical cancer screening disparities through advances in artificial intelligence and nanotechnologies for cellular profiling
Zhenzhong Yang, Jack Francisco, Alexandra S Reese, et al.
Cancers
|
June 4, 2020
Galectins and Ovarian Cancer
Chisa Shimada, Rui Xu, Linah Al-Alem, et al.
Cancers
|
November 2, 2019
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Chiara Bellio, Celeste DiGloria, David R Spriggs, et al.
Page
of 7